A Phase 2, Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN 144 or LN-145) in Patients With Solid Tumors
Phase of Trial: Phase II
Latest Information Update: 20 Dec 2019
Price : $35 *
At a glance
- Drugs Lifileucel (Primary) ; LN 145 (Primary) ; Pembrolizumab (Primary) ; Aldesleukin; Cyclophosphamide; Fludarabine
- Indications Adenocarcinoma; Head and neck cancer; Large cell carcinoma; Malignant melanoma; Non-small cell lung cancer; Solid tumours; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Iovance Biotherapeutics
- 01 Aug 2019 According to an Iovance Biotherapeutics media release, this study has received regulatory approval for conduct in EU and Canada.
- 03 Jul 2019 Planned number of patients changed from 36 to 48.
- 04 Jun 2019 Trial design presented at the 55th Annual Meeting of the American Society of Clinical Oncology